These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 200791)
21. Quantitative computed tomographic evaluation of femoral bone mineral content in renal osteodystrophy compared with radial photon absorptiometry. Sakurai K; Marumo F; Iwanami S; Uchida H; Matsubayashi T Invest Radiol; 1989 May; 24(5):375-82. PubMed ID: 2745019 [TBL] [Abstract][Full Text] [Related]
22. [Vitamin A status of patients with chronic renal failure in relation to renal osteodystrophy]. Stein G; Abendroth K; Kokot F; Keil E; Schöne S; Wessel G; Fünfstück R; Sperschneider H Z Urol Nephrol; 1985 Mar; 78(3):159-65. PubMed ID: 4002896 [TBL] [Abstract][Full Text] [Related]
23. Treatment of renal osteodystrophy in children with dihydrotachysterol and 24,25-dihydroxyvitamin D3. van Diemen-Steenvoorde R; Donckerwolcke RA; Bosch R; Visser WJ; Raymakers JA; Duursma SA Clin Nephrol; 1985 Dec; 24(6):292-9. PubMed ID: 3878249 [TBL] [Abstract][Full Text] [Related]
24. The use of photon absorptiometry in the diagnosis of renal osteodystrophy. Griffiths HJ; Zimmerman RE; Bailey G; Snider R Radiology; 1973 Nov; 109(2):277-81. PubMed ID: 4582537 [No Abstract] [Full Text] [Related]
25. [Evaluation of the mineral content of peripheral bones (radius) by photon-absorption technique in normals as well as in patients with various types of bone diseases (author's transl)]. Runge H; Fengler F; Franke J; Koall W Radiologe; 1980 Oct; 20(10):505-14. PubMed ID: 7444044 [TBL] [Abstract][Full Text] [Related]
26. Bone mineral content after renal transplantation. Placebo-controlled prospective study with 1,25-dihydroxy vitamin D3. Neubauer E; Neubauer N; Ritz E; Dreikorn K; Krause KH Klin Wochenschr; 1984 Jan; 62(2):93-6. PubMed ID: 6368958 [TBL] [Abstract][Full Text] [Related]
27. Photon absorptiometry for non-invasive measurement of bone mineral content. Gupta S; Luna E; Belsky J; Gelfman N; Miller K; Davies T Clin Nucl Med; 1984 Aug; 9(8):435-9. PubMed ID: 6478720 [TBL] [Abstract][Full Text] [Related]
29. Aluminum and renal osteodystrophy in chronic uremia. Berland Y; Grandvuillemin M; Charhon S; Olmer M Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793 [No Abstract] [Full Text] [Related]
30. Histological, hormonal, biochemical and radiological evaluation of vit. D therapy in osteodystrophy patients on RDT. Brancaccio D; Graziani G; Faccini JM; Banfi G; Pedoja G; Watson L J Urol Nephrol (Paris); 1976; 82(4-5):359-62. PubMed ID: 940182 [No Abstract] [Full Text] [Related]
31. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy. Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140 [TBL] [Abstract][Full Text] [Related]
32. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
33. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone. Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749 [No Abstract] [Full Text] [Related]
34. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961 [TBL] [Abstract][Full Text] [Related]
35. [Determination of bone mineral content and correlations with calciotropic hormones in periodic hemodialysis patients]. Anelli F; De Maio P; Girardi V; Papagni S; Rossi G; Cantatore FP; Carrozzo M Minerva Urol Nefrol; 1992; 44(4):265-73. PubMed ID: 1299008 [TBL] [Abstract][Full Text] [Related]
36. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry. Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161 [No Abstract] [Full Text] [Related]
37. Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus. Auwerx J; Dequeker J; Bouillon R; Geusens P; Nijs J Diabetes; 1988 Jan; 37(1):8-12. PubMed ID: 3335279 [TBL] [Abstract][Full Text] [Related]
38. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]